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We developed and compared five scoring systems designed to quantitate therapeutic response in
cases of oropharyngeal candidiasis. We utilized prospectively collected data on 114 patients treated
with several doses of the azole D0870. Patients were infected with fluconazole-susceptible (n  49)
or -resistant organisms (MIC, ⁄16 mg/mL; n  61). Patients with fluconazole resistance had lower
CD4/ cell counts at baseline; more symptoms (P  .0006); a higher frequency of dysgeusia
(P  .004), dysphagia (P  .006), and throat pain (P  .0034); and greater oral coverage by plaques
of Candida. There was no difference between the two groups in terms of colony-forming units, and
any change did not correlate with response to therapy. Resolution of dysphagia (P  .01) and oral
pain (P  .01) correlated well with response to therapy, unlike retrosternal pain and throat pain,
which were also less frequent. Xerostomia, a ‘‘furry’’ taste, and dysgeusia were frequent nonspecific
symptoms. Scoring system C, weighting resolution of a symptom higher than absence of a symptom
at baseline, yielded the best correlation with global outcome (r  0.86) and allows the quantitation
of incomplete but clinically beneficial responses to therapy.
Episodes of oropharyngeal candidiasis (OPC) are almost uni- eral problems have hampered the interpretation of clinical tri-
versal occurrences for patients with AIDS [1, 2]. Esophageal als. First, there are often diverse oral symptoms, some of which
candidiasis is the AIDS-defining event in 13% of patients, may not be attributable to OPC. For example, there is overlap
and 22% develop it during the course of AIDS [3]. OPC and with other HIV-associated conditions such as gingivitis and
esophageal candidiasis tend to be chronic, relapsing, and in- side effects of antiretroviral drugs (such as dry mouth with use
creasingly symptomatic, with progressive immune paresis. of didanosine), so the lack of a symptomatic response may not
OPC in HIV-infected patients usually responds to oral imidaz- be a reliable indicator of persistence of OPC.
ole therapy [4]. However, at later stages of disease, episodes Similarly, signs may be diverse. Pseudomembranous candi-
become more frequent and often refractory to treatment with diasis is the classic form, but OPC may also present as an
these agents [1]. The widespread use of fluconazole, itracona- atrophic form with ulcers, as well as angular cheilitis, with
zole, and ketoconazole has led to the emergence of resistant localized disease at the corners of the mouth, and as an ery-
isolates of Candida albicans [5, 6], especially in the context thematous form with localized discomfort and erythema [10].
of HIV infection [1, 7–9]. The ongoing development of new Assessment of response in patients with extensive oral hairy
agents is necessary to increase the therapeutic options; the main leukoplakia may be imprecise. Individual clinicians are likely
therapy currently available is with intravenous amphotericin to be inconsistent in their assessment of extent of disease.
B, which has attendant problems of toxic effects, particularly In addition, the symptoms of esophageal candidiasis may be
renal impairment. mimicked by a number of other pathologies, such as cytomega-
Previously, the clinical assessment of OPC in therapeutic lovirus or herpes simplex virus esophageal infection, in the
trials has received little attention. In AIDS patients with the presence or absence of OPC. This can make accurate diagnosis
pseudomembranous forms of OPC, disappearance of visible and assessment of therapeutic response with regard to esopha-
lesions, with some diminishment of symptoms, has been taken geal symptoms particularly problematic, unless patients un-
as sufficient evidence of a therapeutic response. However, sev- dergo endoscopic examination [11].
In patients with early AIDS or AIDS-related complex, re-
sponse to treatment can usually be simply evaluated by inspec-
tion of the oral mucosa for the presence or absence of the
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susceptible organisms. Although clearly not a full response or an exclusion criterion. Female patients who were pregnant,
breast-feeding, or using unreliable contraception were also ex-cure with therapy, symptomatic improvement is of benefit to
patients. However, in order to compare one therapy with an- cluded.
other, some objectivity is required in the assessment of re-
sponse, especially in the evaluation of novel antifungal agents.
Description of Studies
From the clinician’s standpoint, it would be helpful to under-
stand more about the utility of certain symptomatic responses Study 003. Study 003 [16] was a two-phase single-dose
study with an open phase (12 subjects) followed by a double-in predicting a mycologic resolution and, conversely, whether
certain symptoms and clinical findings at the start of therapy blind, parallel randomized phase with two doses (12 subjects
in each group). Treatment was given for 5 days. Patients werecould reliably predict the presence of a resistant strain, with a
correspondingly high MIC value for the isolate. excluded from the study if they had previously received fluco-
nazole therapy that failed. Clinical assessments were made atD0870 is a bis-triazole agent with good in vitro activity against
C. albicans and other Candida species [13–15]. Early clinical enrollment, on day 3, at the end of therapy, and on days 7 and
14 after the end of therapy.trial results are encouraging [16, 17]. We had the opportunity to
examine the therapeutic response data from all these trials of Study 012. For study 012 [17], patients who had OPC that
had failed to respond to fluconazole therapy at dosages of⁄100D0870 for OPC to find the optimal means of assessing response
in those with fluconazole-susceptible and -resistant OPC. mg/d for at least 7 days were recruited. This was an open,
nonrandomized trial assessing a single dose of D0870 in 27The aims of the present study were (1) to compare symptoms,
signs, and results of quantitative Candida cultures for patients subjects. Treatment was given for 7 days. Clinical assessment
was made at enrollment, on day 3, at the end of therapy, andwith fluconazole-susceptible and fluconazole-resistant OPC;
(2) to compare assessments of therapeutic response of OPC on days 7 and 14 after the end of therapy.
Study 018. Enrollment criteria for study 018 were the samecaused by azole-susceptible and fluconazole-resistant Candida,
in order to define the optimal criteria for assessing therapeutic as for study 012. The trial was a dose-escalation study in which
48 patients were recruited. Patients in the first cohort wereresponse; and (3) to validate, if possible, a clinical scoring
system that accurately reflects therapeutic response. treated with a given dose of D0870 (dose A), and if the response
rate was£80% and safety had been established, the next cohortTo do this, we investigated whether patients infected with
azole-susceptible and -resistant strains of Candida differ in was treated with a higher dose. The same criteria were used
to elevate the dose further, for a total of five dosing steps.their clinical presentation and determined the correlation (if
any) of therapeutic outcome of individual symptoms with Forty-eight patients were recruited at four doses. Subjects were
assessed for clinical response on days 4, 7, and 10 (end ofglobal outcome. We also examined the effect of treatment on
cfu measurements of isolates from these patients. We sought therapy) and following therapy.
to derive a simple means of assessing the efficacy of antifungal
agents in OPC caused by fluconazole-resistant Candida. We
Clinical Assessment of Efficacy
propose a standard means of objective assessment of outcome
of therapy for OPC caused by azole-resistant Candida in HIV- Comparable clinical data concerning symptoms and clinical
signs of OPC, in addition to the response of each to treatment,infected patients.
In this article, the term fluconazole-refractory OPC is synon- were collected in all the studies. Each symptom was graded as
mild (causing minimum discomfort and not interfering withymous with therapeutic failure of fluconazole, and the term
fluconazole-resistant OPC means OPC that failed to respond everyday activities), moderate (interfering with everyday activ-
ities), or severe (e.g., incapacitating). For study 018, data onto fluconazole and is caused by a fluconazole-resistant strain
of Candida. the symptom ‘‘burning of mouth’’ were not recorded; hence,
the highest grading of ‘‘burning of mouth’’ and ‘‘oral pain’’
in studies 003 and 012 was taken as equivalent to that of ‘‘oral
Methods
pain’’ for study 018.
An oral-cavity examination was performed and estimatedWe analyzed data gathered for three studies (numbered 003
[16], 012 [17], and 018 [unpublished]) of D0870 in HIV- coverage over the soft palate, left and right buccal areas, and
tongue areas was scored as nil, scant, moderate, or confluent.positive individuals with pseudomembranous OPC. All three
were prospective multicenter studies conducted before the in- For study 018, coverage was graded slightly differently, as
absent, 25%, 25%–50%, 51%–75%, 76%–99%, or 100%.troduction of protease inhibitors and mostly during the era of
monotherapy for HIV infection. Adults with normal electrocar- For the purposes of comparison between studies, 25%–75%
coverage was deemed equivalent to ‘‘patchy’’ in the previousdiographic and liver function test findings who had no history
of heart or liver disease were enrolled. Comedication with studies, and 76%–100% was considered equivalent to ‘‘se-
vere’’ or ‘‘confluent.’’ In addition, for study 018, the overallwarfarin, cyclosporine, sulfonylureas, nortriptyline, antiar-
rhythmics, terfenadine, astemizole, or systemic antifungals was coverage of the mucosa was estimated.
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At the end of therapy, the individual outcome for each sign at 357C for 24 hours. Endpoints were determined spectrophoto-
metrically, with the first well showing ⁄50% inhibition beingand symptom was defined as cleared (complete resolution of
signs and symptoms), improvement (partial clearance of signs defined as the MIC. C. albicans ATCC 10231 (MICs: D0870,
0.03 mg/mL; fluconazole, 0.5–2 mg/mL) served as a controland symptoms), failure (no diminishment of signs or symp-
toms), relapse, or unevaluable/misdiagnosis. Global outcome strain. Resistance was defined as an MIC of ⁄16 mg/mL for
fluconazole.was defined as resolved (determined by clinical resolution of
lesions and symptoms), improvement (determined by reduction
in the severity and/or number of symptoms and lesions but
Comparison of Patients with Fluconazole-Susceptible and
without complete resolution), or failure (by persistent signs and
-Resistant Isolates at Baseline
symptoms of equal or greater severity than at baseline). Patients
Patients with fluconazole-susceptible isolates were comparedwere deemed unevaluable if their conditions were judged to be
with those with resistant isolates at study enrollment with re-misdiagnosed, if there were major violations of entry criteria, if
spect to CD4/ cell count, total number of symptoms and fre-any concomitant antifungal agent had been used, or if prether-
quency of individual symptoms, degree of coverage, and cfuapy cultures were negative.
measurement at start of treatment. In the comparison of cover-
age, patients in studies 003 and 012 had coverage expressed
Quantitative Culture Procedure
as absent, patchy, or confluent in four areas (tongue, soft palate,
and left and right buccal mucosae). To enable a comparisonSpecimens were collected by oral swabs from each of the
with study 018 patients (with global coverage estimated as afour areas of the oral cavity. Oral ‘‘swish’’ samples were also
percentage: 0%, 1%–25%, 26%–50%, 51%–75%, 76%–99%,collected. Patients were instructed in the method before being
and 100%), absent was scored as 0, patchy as 1, and confluentasked to rinse and gargle 10 mL of sterile distilled water for
as 2; then the scores for each area were added, for a total scoreat least 20 seconds, before spitting the liquid into a sterile
of 0–8. Zero corresponded with 0%, 1 and 2 with 1%–25%,container. These specimens were stored at 47C until dispatch
3 and 4 with 25%–50%, 5 and 6 with 51%–75%, and 7 andto the microbiology laboratory within 48 hours (usually imme-
8 with 76%–100%. The comparisons were performed with adiately).
Mann-Whitney U test and Wilcoxon rank sum W test.Each oral swab was immersed in 5 mL of sterile PBS in a
sterile tube that was agitated for 15 seconds, and then serial
decimal dilutions in sterile PBS were made; 100-mL aliquots
Comparison of Individual Symptom Response with Global
of the dilutions were subcultured onto Sabouraud dextrose agar.
Outcome
PBS was added to each ‘‘swish’’ sample to make dilutions
Our aims were to measure the predictive power of particularof 1:10, 1:50, 1:100, 1:200, and 1:400. Each dilution was agi-
clinical findings in relation to overall clinical outcome; to ex-tated for 15 seconds, and a 0.1-mL sample from each dilution
amine the relationship, if any, between change in cfu measure-was subcultured onto Sabouraud dextrose agar. In both cases
ments (pretherapy vs. post-therapy) and clinical response; andthe culture plate was then incubated at 377C for 48 hours, and
to determine the strength of association (assessed with use ofthe following day the plate was inspected for colonies typical
Kendall’s tau-B correlation coefficient) in each case. For theof Candida species. The number of cfu per milliliter was quan-
first goal, tables of individual symptom outcome against globaltified as no growth; 10 colonies; 10–100 colonies; 100
outcome were produced, and the data were compared with usecolonies but not countable; or confluent growth.
of Kendall’s tau-B test in each case. For the assessment of cfu
measurements, the median cfu values for before and after ther-
In Vitro Susceptibility Testing
apy were calculated, and the Wilcoxon signed-rank test and
Spearman’s rank correlation test were performed.MIC testing of isolates against fluconazole and D0870 was
performed as follows [13, 18]. RPMI-1640 broth buffered with
MOPS (3-[N-morpholino]propanesulfonic acid) at a pH of 7.0
Testing of Scoring Systems
was the test medium. Five colonies of 1 mm each were picked
off the culture plate, resuspended together in 5 mL of sterile Scoring system A was used initially. This weighted each
clinical symptom on a scale of 0–3, with absent scored as 0;physiological saline, and centrifuged, and the turbidity was
adjusted to a 0.5 McFarland standard with sterile physiological mild, 1; moderate, 2; and severe, 3. Dysphagia was scored
double, 0–6, to weight esophageal involvement adequately, assaline. The resulting 1 1 106-cfu/mL suspension was then di-
luted 1:50 in RPMI broth to give the final inoculum of 2 1 no endoscopy was performed. Each clinical sign was also
scored from 0 to 3 (no lesions, score of 0; few spots, 1; multiple104 cfu/mL. D0870 was dissolved in dimethyl sulfoxide and
fluconazole in water, and each was diluted to give a final dilu- patches, 2; and confluent disease, 3). The total score was de-
rived by subtracting the post-therapy score from the pretherapytion series of 32–0.03 mg/mL in 100-mL microtiter wells after
addition of 100 mL of yeast inoculum. Plates were incubated score. Scoring systems B, C, D, and E were later developed
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Table 1. Scoring systems A–E, showing weighting of individual Results
outcomes of signs and symptoms.
Analysis
Score for outcome in indicated scoring system
Figure 1 illustrates the numbers of patients enrolled in theOutcome of
signs/symptoms A B C D E three studies and their subdivision by history of response to
fluconazole (fluconazole-responsive, fluconazole-refractory)
Worse Sum score* 0 0 01 01 and by results of susceptibility testing of Candida isolates (flu-
Unchanged 0 0 0 0
conazole-susceptible, fluconazole-resistant). Clearly, a historyImproved 1 1 1 1
of clinical response did not always correlate with in vitro sus-Resolved 2 3 2 3
Absent 3 2 3 2 ceptibility to fluconazole. Patients were excluded from the final
subgroup analyses as indicated. Table 2 summarizes response
* See text for explanation of scoring system A.
to therapy in the three studies.
Comparison of Patients with Fluconazole-Susceptible and
and applied to the data, as shown in table 1. In scoring systems
-Resistant Isolates at Baseline
B–E, a score was given for the degree of change in each sign
or symptom. These individual scores were then added together CD4/ cell count. There was a significant difference in
CD4/ cell counts between the fluconazole-resistant and -sus-to give an overall score.
Figure 1. Enrollment of patients
in the three studies analyzed and
their classification by clinical re-
sponse and in vitro susceptibility to
fluconazole (Flu fluconazole; QTc
interval  Q-T interval, corrected
for heart rate).
/ 9c63$$mr08 02-22-99 13:35:55 cida UC: CID
591CID 1999;28 (March) Therapeutic Response of Candidiasis in AIDS
Table 2. Summary of data concerning enrollment, previous response and susceptibility to fluconazole, and response to D0870 in the three
studies. The data shown are numbers of patients.
Elevated MIC of Clinical response to D0870
Study Patients Fluconazole fluconazole Eligible for
no. enrolled therapy failed (⁄16 mg/mL) this analysis Resolution Improvement Failure
003 39 0 4 33 27 4 2
012 27 26 16 26 1 16 9
018 48 48 36 40 9 22 9
Total 114 74 56 99 37 44 20
ceptible groups (Mann-Whitney, P  .0001). The median zole-resistant strains. Burning of the mouth is a less frequent
symptom in disease due to fluconazole-susceptible strains thanCD4/ cell count at baseline for patients with resistant isolates
(n  61) was 6 (quartiles: 2, 22.5) 1 106/L, and for those with in that due to fluconazole-resistant strains. Oral pain was the
second most frequent symptom in disease due to fluconazole-susceptible isolates (n  49), 19 (quartiles: 10, 74) 1 106/L.
Coverage. Percentage of oral coverage was significantly susceptible or fluconazole-resistant isolates. A Kendall correla-
tion coefficient was generated to compare any change in symp-greater at baseline in the fluconazole-resistant group than in
the fluconazole-susceptible group (Mann-Whitney, P .0003). tom with global outcome to determine the correlation between
symptom outcome (worse, unchanged, improved, resolved) andColony-forming units. There was no difference in cfu mea-
surements at baseline between patients with OPC due to fluco- global outcome. This was done for all patients and then for
the two subgroups with OPC due to fluconazole-susceptiblenazole-resistant Candida isolates and those with OPC due to
fluconazole-susceptible strains (P  .64). and -resistant organisms. The results are shown in table 4.
Improvement (diminishment) in certain symptoms (dysphagia
and oral pain) correlates most closely with overall clinical
Symptoms
improvement.
The presence or absence of the ‘‘burning of mouth’’ symp-Number and frequency of symptoms. There was a signifi-
cant difference in both the number of symptoms and the fre- tom correlates well with that of oral pain. There was poor
agreement between change in ‘‘furry’’ taste and change inquency of individual symptoms between the fluconazole-
resistant and -susceptible groups. The median numbers of tongue lesions (agreement, 38%; kappa  0.14), and ‘‘furry’’
taste did not correlate with the clinical sign of tongue coating.symptoms at baseline for patients completing the study who
had fluconazole-resistant disease (n  54) and fluconazole- Dysgeusia was the most frequent symptom in the study, irre-
spective of the presence of OPC, and had a relatively poorsusceptible disease (n  45) were 3 and 1, respectively
(P  .0006). Among initial symptoms, the frequency of dys- correlation with outcome. Xerostomia (dry mouth) was also a
frequent symptom but again correlated poorly with outcome.geusia (P .0038), dysphagia (P  .006), and throat pain (P
.0034) but not of retrosternal pain or oral pain was significantly White plaques (as reported by the patient) showed a close
correlation with objective (i.e., physician-described) measuresgreater in patients with resistant disease (table 3).
Symptom frequencies are shown in table 3. The data are of outcome.
consistent with certain symptoms of OPC being more common
than others, and some symptoms are more common in flucona-
Measurements of Colony-Forming Units
zole-resistant OPC than in fluconazole-susceptible OPC. Dys-
phagia is an infrequent symptom in disease due to fluconazole- The change in median number of cfus of all fungal isolates
between the start and end of therapy was compared by meanssusceptible Candida but is frequent in disease due to flucona-
Table 3. Number and percentage of patients (including unevaluable ones) in each study with indicated symptoms of oropharyngeal candidiasis
on enrollment.
Study Burning Oral Retrosternal Throat ‘‘Furry’’
no. Dysphagia of mouth Dysgeusia pain Xerostomia pain pain taste
003 11 (28) 7 (18) 17 (44) 10 (26) 21 (54) 4 (10) 11 (28) 16 (41)
012 20 (74) 13 (48) 21 (78) 15 (56) 19 (70) 10 (37) 18 (67) 22 (81)
018 20 (42) NC 30 (63) 30 (63) NC 13 (27) 19 (40) NC
NOTE. NC  data not collected.
/ 9c63$$mr08 02-22-99 13:35:55 cida UC: CID
592 Hood et al. CID 1999;28 (March)
Table 4. Kendall correlation coefficients of agreement between individual symptom outcome and global outcome.
All Patients with flu- Patients with flu-
Symptom patients P value resistant OPC P value susceptible OPC P value
Dysphagia .42 .01 .31 .06 .61 .01
Dysgeusia .23 .04 .16 .23 .34 .09
Oral pain .44 .01 .36 .02 .52 .01
Retrosternal pain .49 .01 .61 .01 .36 .29
Throat pain .35 .01 .45 .01 .24 .31
NOTE. Flu  fluconazole; OPC  oropharyngeal candidiasis.
of the Wilcoxon matched-pairs signed-ranks test. The values than no change in the symptom but was otherwise the same as
scoring system C. Scoring system E (correlation, 0.82) was thefor fluconazole-susceptible vs. -resistant disease were com-
pared with Spearman’s rank correlation test. same as scoring system D, except resolution of a symptom was
weighted (/3) higher than absence of a symptom (/2).Among cases of fluconazole-susceptible OPC (n  40), the
median starting cfu score was 4 (quartiles, 3 and 4), equivalent Figures 4–8 show the degree of correlation between changes
in scores for symptoms and changes in scores for degree ofto a value of 100 cfu/mL. There was a nonsignificant reduc-
tion in cfu score at end of treatment, to 3 (10–100 cfu/mL; coverage by oral patches (signs) following treatment. For each
scoring system, in a considerable proportion of patients, a ten-quartiles, 3 and 4). There was no correlation with clinical out-
come (rs  0.26; P  .11). dency emerged for comparatively greater improvement in
symptoms than reduction in oral coverage following treatment.Among cases of fluconazole-resistant OPC (n  52), the
median cfu value was 4 (quartiles, 3 and 4) at both baseline and This was most marked for system B and C scores. Our analysis
suggests dysphagia, oral pain, and oral burning are the mostend of therapy. Again, there was no correlation with clinical
outcome (rs  0.28; P  .04). useful symptoms to include in the scoring system. Xerostomia
and dysgeusia are frequent symptoms, irrespective of the pres-
ence of OPC, and are best excluded from assessments of effi-
Scoring Systems
cacy. Scoring system C gives the best degree of differentiation
between the groups where symptoms resolved, improved, orTo assess the five clinical scoring systems against global
outcome, Spearman’s rank correlation test was performed for remained unchanged/worsened, with no overlap between those
whose therapy failed and those whose symptoms cleared. Theeach scoring system. The patients were divided into two groups
(fluconazole-susceptible vs. fluconazole-resistant disease) on data also demonstrate that scoring system C works equally
the basis of MIC data (values of⁄16 mg/mL defined resistance
and values16 mg/mL defined susceptibility). Global outcome
of OPC was defined as follows. OPC was considered resolved
if all oral lesions and symptoms of disease resolved, improved
if there was some diminishment of oral lesions or symptoms
or both, unchanged if oral lesions were unchanged, and worse
if there was greater coverage with lesions at the end of therapy.
Figures 2 and 3 show outcomes according to scoring systems
A and C for fluconazole-resistant and -susceptible disease. Res-
olution was primarily determined by clearing of patches in the
mouth. Equally good differentiation between outcomes can be
seen for fluconazole-resistant and -susceptible disease.
Scoring system A, a simple-sum method, was initially tried
but differentiated poorly between different outcomes, yielding
a correlation of 00.37 (figure 2). Scoring system B weighted
the absence of a symptom throughout more positively (/3)
than resolution of the symptom (/2), and showed a correlation
of 0.81 between score and global outcome. Scoring system C
weighted resolution (/3) as a better outcome than absence
of a symptom throughout (/2) (figure 3); this gave the best Figure 2. Change in symptoms vs. change in signs following ther-
correlation (0.86). Scoring system D (correlation, 0.78) apy, according to scoring system A (l  fluconazole MIC of ⁄16
mg/mL; s  fluconazole MIC of 16 mg/mL).weighted worsening of a symptom (01) as a worse outcome
/ 9c63$$mr08 02-22-99 13:35:55 cida UC: CID
593CID 1999;28 (March) Therapeutic Response of Candidiasis in AIDS
Figure 5. Scoring system B vs. global outcome. The plot shows
Figure 3. Change in symptoms vs. change in signs following ther- degree of correlation between changes in scores for symptoms and
apy, according to scoring system C (l  fluconazole MIC of ⁄16 those for signs following treatment. A higher score represents a better
mg/mL; s  fluconazole MIC of 16 mg/mL). outcome (l  fluconazole MIC of ⁄16 mg/mL; s  fluconazole
MIC of 16 mg/mL).
well for fluconazole-resistant and -susceptible disease (figures
3 and 6). zole solution has good efficacy in a majority of those with
fluconazole-refractory disease [20, 21]. Large doses of oral
amphotericin B solution (e.g., 200 mg four times daily) are
Discussion
partially effective [22]. Intravenous amphotericin B in conven-
tional or lipid-associated preparations can be used as a lastTreatment options for fluconazole-refractory OPC are lim-
ited. High doses of itraconazole capsules or ketoconazole may resort [19]. Few data exist regarding the efficacy of and optimal
dosage for this latter option.produce a response, but this is often short-lived [19]. Itracona-
Figure 4. Scoring system A vs. global outcome. The plot shows Figure 6. Scoring system C vs. global outcome. The plot shows
degree of correlation between changes in scores for symptoms anddegree of correlation between changes in scores for symptoms and
those for signs following treatment. A negative score represents an those for signs following treatment. A higher score represents a better
outcome (l  fluconazole MIC of ⁄16 mg/mL; s  fluconazoleimprovement (l  fluconazole MIC of⁄16 mg/mL; s  fluconazole
MIC of 16 mg/mL). MIC of 16 mg/mL).
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involvement. It has been suggested that xerostomia correlates
with clinical failure of fluconazole, because reduced saliva pro-
duction would reduce the amount of fluconazole reaching the
oral cavity. This was not confirmed by this study with D0870,
another azole secreted in saliva, as the presence of xerostomia
at baseline did not correlate with a poor outcome.
The value of susceptibility testing is also emphasized by
these data, as it is apparent that patients’ fluconazole therapy
may fail for many reasons, one of which is resistance of the
infecting organism(s) (76% in this series). Access to suscepti-
bility testing may well prove to be a valuable clinical tool with
the continued emergence of azole-resistant isolates of
C. albicans and other Candida species.
The data from the three studies provided a good range of
outcomes; there was a good distribution of complete, partial,
and no responses, necessary to develop and test a scoring sys-
tem (table 1). An intuitive approach to formulating a scoring
system would rate severity of signs and symptoms at the begin-Figure 7. Scoring system D vs. global outcome. The plot shows
degree of correlation between changes in scores for symptoms and ning and end of therapy and would score response on the
those for signs following treatment. A higher score represents a better difference between the two (scoring system A). However, the
outcome (l  fluconazole MIC of ⁄16 mg/mL; s  fluconazole
disadvantage of this is that ‘‘absent throughout’’ equates withMIC of 16 mg/mL).
‘‘severe throughout.’’ Unless the baseline total score is inte-
grated into the score, a poor correlation with other outcome
measures will be attained, as in scoring system A. In compari-Our further detailed analysis of the three studies of treatment
of fluconazole-susceptible and fluconazole-resistant pseudo- son, scoring system C is better because it reflects the severity
of disease, in terms of number of symptoms, as well as anymembranous OPC has revealed that there are marked differ-
ences in symptomatology, objective signs of disease, mycol- change following therapy.
In terms of using scores for degree of coverage of the oralogy, and therapeutic outcome between the two groups. Few
previous studies have carefully examined these issues, and none mucosa by plaques of Candida, if the score includes ‘‘confluent’’
coverage for an area, then this must be attainable. From the datahave been able to compare the two groups prospectively. Our
analysis is limited by the two groups’ imprecise matching by it became clear that ‘‘confluent’’ coverage was attainable in buccal
CD4 cell count and stage of AIDS. The median CD4 cell
counts were 20 1 106/L in both groups, however. Despite
this caveat, we still believe the data are valuable. In addition,
this work represents the first attempt to define a relationship
between assessment of symptoms of OPC in patients with HIV
infection and AIDS and clinical outcome following treatment
with an azole.
We noted a large diversity of therapeutic outcome of individ-
ual symptoms and considerable overlap with other conditions.
We found that the most useful symptoms to assess are dyspha-
gia and oral pain (described as pain, burning, or discomfort).
Loss of appetite and dysphagia lead to weight loss, and this
may further worsen the clinical condition. Though cure may
not be possible, a symptomatic response may well enable a
patient to increase food intake considerably and improve his
or her sense of well-being.
There was a poor correlation between objective and subjec-
tive measures of response, especially in cases of fluconazole-
resistant disease. Many patients had a beneficial symptomatic
Figure 8. Scoring system E vs. global outcome. The plot showsresponse, with little change in the appearance of their mouths.
degree of correlation between changes in scores for symptoms and
Of particular note is the finding that there was poor agreement those for signs following treatment. A higher score represents an
between change in tongue lesions and change in ‘‘furry’’ taste, improved outcome (l  fluconazole MIC of⁄16 mg/mL; s  fluco-
nazole MIC of 16 mg/mL).implying that ‘‘furry’’ taste is not necessarily related to tongue
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Table 5. Proposed scoring system for assessment of OPC in patients patients with OPC due to fluconazole-susceptible Candida and
with AIDS. those with OPC due to fluconazole-resistant Candida. Benefi-
cial symptomatic responses follow therapy, but often without
Symptoms
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